Comparative Pharmacology
Head-to-head clinical analysis: ENBREL versus SIMPONI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENBREL versus SIMPONI.
ENBREL vs SIMPONI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tumor necrosis factor (TNF) inhibitor; etanercept is a dimeric fusion protein consisting of the extracellular ligand-binding portion of human TNF receptor p75 linked to the Fc portion of human IgG1. It binds to soluble and membrane-bound TNF, thereby blocking TNF-mediated inflammatory responses.
Golimumab is a human monoclonal antibody that binds to and neutralizes tumor necrosis factor alpha (TNF-α), inhibiting its interaction with TNF receptors and thereby reducing inflammatory responses.
50 mg subcutaneous injection once weekly
Simponi (golimumab) is administered subcutaneously. For adult rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: 50 mg once monthly. For ulcerative colitis: 200 mg subcutaneously at week 0, then 100 mg at week 2, then 100 mg every 4 weeks.
None Documented
None Documented
Approximately 102 hours (range 68–170 hours) after subcutaneous administration in adults; prolonged in elderly and patients with renal impairment; supports every 2-week dosing.
Terminal elimination half-life approximately 12-14 days (mean 12.3 days in rheumatoid arthritis patients). Supports subcutaneous dosing every 2 weeks.
Renal: negligible; Biliary/Fecal: not significantly eliminated; primarily degraded via proteolysis into amino acids.
Primarily degraded into small peptides and amino acids via reticuloendothelial system; no significant renal or biliary elimination. Less than 0.1% excreted unchanged in urine.
Category C
Category C
TNF-alpha Inhibitor
TNF-alpha Inhibitor